Rothner 1999a.

Study characteristics
Methods	Randomized, double‐blind, placebo‐controlled, parallel‐group 3‐attack trial of oral sumatriptan
Participants	Participants from 62 centers in 7 countries were 12‐17 years of age with a minimum 6‐month history of migraine with or without aura per IHS 1988 criteria and 1‐6 attacks per month Randomized (N = 347); withdrawn (N = 117); intention‐to‐treat and primary efficacy analysis (N = 273)
Interventions	Each participant treated 1 migraine with oral sumatriptan 25 mg, 50 mg, 100 mg, or placebo. No maximum time after the onset of migraine was specified.
Outcomes	Headache relief at 2 h (moderate or severe pain intensity reduced to no or mild pain) Pain free at 2 h Presence of nausea within 4 h Use of rescue medication within 24 h Recurrence of migraine within 4‐24 h Adverse events Other reported outcomes: Presense of photophobia or phonophobia within 4 h Other time points (headache relief at 1 h was primary outcome in study) Time to meaningful relief
Headache severity scale	4‐point scale (none, mild, moderate, severe)
Funding source	GlaxoSmithKline
Publication	Abstract and clinical trial registry
Notes	Headache alleviation: reduction in headache from grade 3 or 2 to grade 1 or 0 within 2 h where 3 = headache, I can't do anything; 2 = headache, I can do easy activities; 1 = headache, I can carry on as usual; and 0 = no headache. Funding: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: described as randomized but no details
Allocation concealment (selection bias)	Unclear risk	Comment: no description of allocation concealment
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Comment: no description of efforts to maintain blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	Comment: missing outcome data balanced across intervention groups
Selective reporting (reporting bias)	Low risk	Comment: all expected outcomes reported